Organon to halt development of endometriosis pain drug after mid-stage trial failure

(Reuters) -Organon said on Wednesday it will discontinue the development of its experimental drug, after it failed to reduce pain in women suffering from endometriosis in a mid-stage study.

The trial tested the drug, OG-6219, in women aged 18 to 49 who had moderate-to-severe endometriosis-related pain, but results showed no significant improvement compared to a placebo.

Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, often causing chronic pelvic pain and infertility.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)